-
1
-
-
77952322021
-
-
A.P.P. Pharmaceuticals, Package Insert, Schaumburg, IL
-
Protamine Sulfate Injection USP 2008, A.P.P. Pharmaceuticals, Package Insert, Schaumburg, IL.
-
(2008)
Protamine Sulfate Injection USP
-
-
-
3
-
-
77952323171
-
-
US Patent No. 5,877,153
-
Harris, R.B., Sobel, M., 1999. Heparin-binding peptides. US Patent No. 5,877,153.
-
(1999)
Heparin-binding peptides
-
-
Harris, R.B.1
Sobel, M.2
-
4
-
-
77952320856
-
Heparin-binding peptides
-
US Patent No. 6,200,955
-
Harris, R.B., Sobel, M., 2001. Heparin-binding peptides. US Patent No. 6,200,955.
-
(2001)
-
-
Harris, R.B.1
Sobel, M.2
-
5
-
-
0030017370
-
Heparin neutralization with methylene blue, hexadimethrine, or vancomycin after cardiopulmonary bypass
-
Kikura M., Lee M.K., Levy J.H. Heparin neutralization with methylene blue, hexadimethrine, or vancomycin after cardiopulmonary bypass. Anesth. Analg. 1996, 83:223-227.
-
(1996)
Anesth. Analg.
, vol.83
, pp. 223-227
-
-
Kikura, M.1
Lee, M.K.2
Levy, J.H.3
-
6
-
-
0031984680
-
Adverse events after protamine administration in patients undergoing cardiopulmonary bypass: risks and predictors of under-reporting
-
Kimmel S.E., Sekeres M.A., Berlin J.A., Goldberg L.R., Strom B.L. Adverse events after protamine administration in patients undergoing cardiopulmonary bypass: risks and predictors of under-reporting. J. Clin. Epidemiol. 1998, 51:1-10.
-
(1998)
J. Clin. Epidemiol.
, vol.51
, pp. 1-10
-
-
Kimmel, S.E.1
Sekeres, M.A.2
Berlin, J.A.3
Goldberg, L.R.4
Strom, B.L.5
-
7
-
-
0036261833
-
Mortality and adverse events after protamine administration in patients undergoing cardiopulmonary bypass
-
Kimmel S.E., Sekeres M., Berlin J.A., Ellison N. Mortality and adverse events after protamine administration in patients undergoing cardiopulmonary bypass. Anesth. Analg. 2002, 94:1402-1408.
-
(2002)
Anesth. Analg.
, vol.94
, pp. 1402-1408
-
-
Kimmel, S.E.1
Sekeres, M.2
Berlin, J.A.3
Ellison, N.4
-
8
-
-
44849115945
-
Contaminated heparin associated with adverse clinical events and activation of the contact system
-
Kishimoto T.K., Viswanathan K., Ganguly T., Elankumaran S., Smith S., Pelzer K., Lansing J.C., Sriranganathan N., Zhao G., Galcheva-Gargova Z., Al-Hakim A., Bailey G.S., Fraser B., Roy S., Rogers-Cotrone T., Buhse L., Whary M., Fox J., Nasr M., Dal Pan G.J., Shriver Z., Langer R.S., Venkataraman G., Austen K.F., Woodcock J., Sasisekharan R. Contaminated heparin associated with adverse clinical events and activation of the contact system. N. Engl. J. Med. 2008, 358:2457-2467.
-
(2008)
N. Engl. J. Med.
, vol.358
, pp. 2457-2467
-
-
Kishimoto, T.K.1
Viswanathan, K.2
Ganguly, T.3
Elankumaran, S.4
Smith, S.5
Pelzer, K.6
Lansing, J.C.7
Sriranganathan, N.8
Zhao, G.9
Galcheva-Gargova, Z.10
Al-Hakim, A.11
Bailey, G.S.12
Fraser, B.13
Roy, S.14
Rogers-Cotrone, T.15
Buhse, L.16
Whary, M.17
Fox, J.18
Nasr, M.19
Dal Pan, G.J.20
Shriver, Z.21
Langer, R.S.22
Venkataraman, G.23
Austen, K.F.24
Woodcock, J.25
Sasisekharan, R.26
more..
-
9
-
-
0029044753
-
Heparin neutralization by recombinant platelet factor 4 and protamine
-
Levy J.H., Cormack J.G., Morales A. Heparin neutralization by recombinant platelet factor 4 and protamine. Anesth. Analg. 1995, 81:35-37.
-
(1995)
Anesth. Analg.
, vol.81
, pp. 35-37
-
-
Levy, J.H.1
Cormack, J.G.2
Morales, A.3
-
11
-
-
0042623486
-
Dramatic post-cardiotomy outcome, due to severe anaphylactic reaction to protamine
-
Panos A., Orrit X., Chevalley C., Kalangos A. Dramatic post-cardiotomy outcome, due to severe anaphylactic reaction to protamine. Eur. J. Cardiothorac. Surg. 2003, 24:325-327.
-
(2003)
Eur. J. Cardiothorac. Surg.
, vol.24
, pp. 325-327
-
-
Panos, A.1
Orrit, X.2
Chevalley, C.3
Kalangos, A.4
-
12
-
-
0026457594
-
Neutralization of the antithrombotic effects of heparin and Fraxiparin by protamine sulfate
-
Racanelli A., Fareed J. Neutralization of the antithrombotic effects of heparin and Fraxiparin by protamine sulfate. Thromb. Res. 1992, 68:211-222.
-
(1992)
Thromb. Res.
, vol.68
, pp. 211-222
-
-
Racanelli, A.1
Fareed, J.2
-
13
-
-
0842264034
-
Novel concatameric heparin-binding peptides reverse heparin and low-molecular-weight heparin anticoagulant activities in patient plasma in vitro and in rats in vivo
-
Schick B.P., Maslow D., Moshinski A., San Antonio J.D. Novel concatameric heparin-binding peptides reverse heparin and low-molecular-weight heparin anticoagulant activities in patient plasma in vitro and in rats in vivo. Blood 2004, 103:1356-1363.
-
(2004)
Blood
, vol.103
, pp. 1356-1363
-
-
Schick, B.P.1
Maslow, D.2
Moshinski, A.3
San Antonio, J.D.4
-
14
-
-
0033378046
-
Development of heparin antagonists with focused biological activity
-
Shenoy S., Sobel M., Harris R.B. Development of heparin antagonists with focused biological activity. Curr. Pharm. Des. 1999, 5:965-986.
-
(1999)
Curr. Pharm. Des.
, vol.5
, pp. 965-986
-
-
Shenoy, S.1
Sobel, M.2
Harris, R.B.3
-
15
-
-
23044475017
-
Efficacy and safety of heparinase I versus protamine in patients undergoing coronary artery bypass grafting with and without cardiopulmonary bypass
-
Stafford-Smith M., Lefrak E.A., Qazi A.G., Welsby I., Barber L., Hoeft A., Dorenbaum A., Mathias J., Rochon J.J., Newman M.F. Efficacy and safety of heparinase I versus protamine in patients undergoing coronary artery bypass grafting with and without cardiopulmonary bypass. Anesthesiology 2005, 103:229-240.
-
(2005)
Anesthesiology
, vol.103
, pp. 229-240
-
-
Stafford-Smith, M.1
Lefrak, E.A.2
Qazi, A.G.3
Welsby, I.4
Barber, L.5
Hoeft, A.6
Dorenbaum, A.7
Mathias, J.8
Rochon, J.J.9
Newman, M.F.10
-
16
-
-
77952323708
-
Peptides for heparin and low molecular weight heparin anticoagulation reversal
-
United States Patent No. 5,534,619
-
Wakefield, T.W., Stanley, J.C., Andrews, P.C., 1996. Peptides for heparin and low molecular weight heparin anticoagulation reversal. United States Patent No. 5,534,619.
-
(1996)
-
-
Wakefield, T.W.1
Stanley, J.C.2
Andrews, P.C.3
-
17
-
-
0025305892
-
A prospective study of the risk of an immediate adverse reaction to protamine sulfate during cardiopulmonary bypass surgery
-
Weiler J.M., Gellhaus M.A., Carter J.G., Meng R.L., Benson P.M., Hottel R.A., Schillig K.B., Vegh A.B., Clarke W.R. A prospective study of the risk of an immediate adverse reaction to protamine sulfate during cardiopulmonary bypass surgery. J. Clin. Immunol. 1990, 85:713-719.
-
(1990)
J. Clin. Immunol.
, vol.85
, pp. 713-719
-
-
Weiler, J.M.1
Gellhaus, M.A.2
Carter, J.G.3
Meng, R.L.4
Benson, P.M.5
Hottel, R.A.6
Schillig, K.B.7
Vegh, A.B.8
Clarke, W.R.9
-
18
-
-
0024598118
-
Association of protamine IgE and IgG antibodies with life-threatening reactions to intravenous protamine
-
Weiss M.E., Nyhan D., Peng Z.K., Horrow J.C., Lowenstein E., Hirshman C., Adkinson N.F. Association of protamine IgE and IgG antibodies with life-threatening reactions to intravenous protamine. N. Engl. J. Med. 1989, 320:886-892.
-
(1989)
N. Engl. J. Med.
, vol.320
, pp. 886-892
-
-
Weiss, M.E.1
Nyhan, D.2
Peng, Z.K.3
Horrow, J.C.4
Lowenstein, E.5
Hirshman, C.6
Adkinson, N.F.7
-
19
-
-
77952319263
-
Hemodynamic changes after protamine administration
-
Welsby I., Newman M.F., Phillips-Bute B., Messier R.H., Kakkis E.D., Stafford-Smith M. Hemodynamic changes after protamine administration. Anesthesiology 2005, 103:229-240.
-
(2005)
Anesthesiology
, vol.103
, pp. 229-240
-
-
Welsby, I.1
Newman, M.F.2
Phillips-Bute, B.3
Messier, R.H.4
Kakkis, E.D.5
Stafford-Smith, M.6
|